Get started
Author

Régine Buffels

Single‐Dose Liposomal Amphotericin B in the Treatment of Visceral Leishmaniasis in India: A Multicenter Study
2003 · S. Sundar, T. K. Jha, et al. · Clinical Infectious Diseases · 134
PDF
Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study.
2002 · S Sundar, T K Jha, et al. · American Journal of Tropical Medicine and Hygiene · 99
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
2019 · Benjamin Turner, Bruce A. C. Cree, et al. · Journal of Neurology · 86
PDF
Pharmacokinetic Study of Tenofovir Disoproxil Fumarate Combined with Rifampin in Healthy Volunteers
2005 · J. A. H. Droste, C. P. W. G. M. Verweij-van Wissen, et al. · Antimicrobial Agents and Chemotherapy · 79
PDF
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
2018 · Eva Havrdová, Douglas L Arnold, et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 58
PDF
Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I–II study
2002 · A Fassas, R Buffels, et al. · British Journal of Haematology · 43
Efficacy and safety of ocrelizumab in patients with relapsing‐remitting multiple sclerosis with suboptimal response to prior disease‐modifying therapies: A primary analysis from the phase 3b CASTING single‐arm, open‐label trial
2021 · Patrick Vermersch, Celia Oreja‐Guevara, et al. · European Journal of Neurology · 34
PDF
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis
2023 · Alexandra Garcia, Emilie Dugast, et al. · Neurology Neuroimmunology & Neuroinflammation · 28
PDF
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis
2020 · H-P Hartung, T Berger, et al. · Multiple Sclerosis and Related Disorders · 27
PDF
Safety of high‐dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia
2003 · Athanasios Fassas, Regine Buffels, et al. · British Journal of Haematology · 26
Pregnancy outcomes in patients treated with ocrelizumab
2019 · C. Oreja-Guevara, S. Wray, et al. · Journal of the Neurological Sciences · 17
PDF
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial
2024 · Hans-Peter Hartung, Thomas Berger, et al. · Journal of Neurology · 7
PDF
SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab
2023 · Jeffrey L. Bennett, Kazuo Fujihara, et al. · Frontiers in Neurology · 6
PDF
Pregnancy Outcomes in Patients Treated with Ocrelizumab
2020 · Celia Oreja-Guevara, Sibyl Wray, et al. · Multiple Sclerosis and Related Disorders · 6
Low immunogenicity but reduced bioavailability of an interferon beta-1a biosimilar compared with its biological parent: results of MATRIX, a cross-sectional, multicenter phase 4 study
2015 · Carlos Cuevas, Florian Deisenhammer, et al. · Biosimilars · 6
PDF
Recently Diagnosed Early-Stage RRMS: NEDA, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data From the Ocrelizumab Phase IIIb ENSEMBLE Study (2261)
2021 · Timothy Vollmer, Mark S. Freedman, et al. · Neurology · 3
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis (P5.407)
2017 · Ludwig Kappos, Stephen Hauser, et al. · Neurology · 2
038 Pregnancy outcomes in patients treated with ocrelizumab
2022 · Peter Brex, Celia Oreja-Guevara, et al. · Journal of Neurology Neurosurgery & Psychiatry · 1
SAkuraBONSAI: A Prospective, Open-label Study of Satralizumab Investigating Novel Imaging, Biomarker, and Clinical Outcomes in Patients with Aquaporin-4-IgG-seropositive (P15.AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) (P15-1.002)
2022 · Anthony Traboulsee, Kazuo Fujihara, et al. · Neurology · 1
Efficacy and Safety of Ocrelizumab in Patients With RRMS With Suboptimal Response to Prior Disease-Modifying Therapies: 3-Year Data From CASTING and LIBERTO (LIBERTO 1-Year Interim Results) (P5-4.003)
2022 · Patrick Vermersch, Celia Oreja-Guevara, et al. · Neurology · 1
Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1‑year interim results)
2019 · P. Vermersch, J.P. Eralinna, et al. · Journal of the Neurological Sciences · 1
No Evidence of Disease Activity on Ocrelizumab Treatment in Patients With Early Relapsing Multiple Sclerosis: Pooled Analysis of the Phase III OPERA Studies (P4.391)
2017 · Eva Havrdova, Stephen Hauser, et al. · Neurology · 1
Efficacy of Ocrelizumab on Brain MRI Outcomes in Patients with Early Relapsing Multiple Sclerosis: Pooled Analysis of the OPERA Studies (P6.338)
2017 · Anthony Traboulsee, Stephen Hauser, et al. · Neurology · 1
Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4‐Year CASTING – LIBERTO Trial
2026 · Patrick Vermersch, Ralph H. B. Benedict, et al. · European Journal of Neurology
Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study (P7-3.003)
2023 · Robert Bermel, Joep Killestein, et al. · Neurology
Works count: 51
Citation count: 667
H-index: 11
I10-index: 11
Year
Topic
Type